CAJ | 학술논문

目的比较阿托伐他汀与中药降脂合剂对冠心病患者血脂、hs-CRP、血管内皮细胞(CEC)及颈动脉内-中膜厚度(IMT)的影响.方法选取冠心病患者133例,随机分为阿托伐他汀组和降脂合剂组,观察服药前、服药后1月、6月时血脂(TC、TG、LDL-C、HDL-C)、CEC、hs-CRP水平及IMT的变化.结果(1)两组治疗1月时出现TC、LDL-C水平的下降,6月时下降更明显(P<0.01),且降脂合剂组TG水平明显低于阿托伐他组(P<0.05);(2)两组治疗1月时CEC、hs-CRP水平开始下降,6月时下降更为明显(P<0.01),且降脂合剂组CEC、hs-CRP水平明显低于阿托伐他组(P<0.05);两组治疗6月时IMT厚度呈现下降的趋势(P<0.05),但两组相比无显著差别.(3)服药至10月时,降脂合剂组与阿托伐他汀组相比,出现心血管事件及需要行PCI或冠脉搭桥患者有显著差别(1.53﹪VS7.35﹪,P<0.05).结论降脂合剂与阿托伐他汀相比对冠心病患者有更好的保护血管内皮及稳定斑块的作用.
목적비교아탁벌타정여중약강지합제대관심병환자혈지、hs-CRP、혈관내피세포(CEC)급경동맥내-중막후도(IMT)적영향.방법선취관심병환자133례,수궤분위아탁벌타정조화강지합제조,관찰복약전、복약후1월、6월시혈지(TC、TG、LDL-C、HDL-C)、CEC、hs-CRP수평급IMT적변화.결과(1)량조치료1월시출현TC、LDL-C수평적하강,6월시하강경명현(P<0.01),차강지합제조TG수평명현저우아탁벌타조(P<0.05);(2)량조치료1월시CEC、hs-CRP수평개시하강,6월시하강경위명현(P<0.01),차강지합제조CEC、hs-CRP수평명현저우아탁벌타조(P<0.05);량조치료6월시IMT후도정현하강적추세(P<0.05),단량조상비무현저차별.(3)복약지10월시,강지합제조여아탁벌타정조상비,출현심혈관사건급수요행PCI혹관맥탑교환자유현저차별(1.53﹪VS7.35﹪,P<0.05).결론강지합제여아탁벌타정상비대관심병환자유경호적보호혈관내피급은정반괴적작용.
Objectives To evaluated the effect of atorvastatin and lipid-lowering mixture on serum lipids,hs-C-reactive protein(hs-CRP),circulating endothelium cels (CEC) and Carotid artery intima-media thickness(IMT) in patiente with coronary heart disease(CHD). Methods 133 patients with CHD were randomized to receive atorvastatin (20mg/d, group 1) or lipid-lowering mixture(group 2) after admition. Serum lipids, hs-CRP,CEC and IMT were assessed at baseline, 1 month and 6 months after treatment. Results (1) Compared to baseline, the levels of total cholesterol(TC),LDL-C were significantly decreased after 1 month(P<0.05) and 6 months (P<0.01) in two groups,and the level of triglycerides(TC) was significantly lower in group2 than group 1. (2) The levels of CEC and hs-CRP significantly decreased at 1 month(P<0.05)and 6 moths (P<0.01) compared to baseline in both groups, especialy lower in group2; In both groups, IMT was decreased at 6 months, but there was no significant difference between tow groups. (3) At 10 months, patients had cardiovascular events and needed PCI or CABG in group 2 was significantly reduced compared to group1(1.53﹪VS7.35﹪,P<0.05). Conclusion Lipid-lowering mixture is superior to atorvastatin(20mg) in protecting endothelial function and stabilizing plaque.